COMP <GO>
GMED vs SOLV // EV/EBITDA & P/E VALUATION
Globus Medical Inc. (NYSE) VS. Solventum Corporation (NYSE) • 15-METRIC TALLY: GMED 7
— SOLV 6
▲ EV/EBITDA & P/E VALUATION LEADER: SOLV
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
valuation
17.6x
LAST: $81.33 (-2.67%) • MKT CAP: $14.22B
valuation
7.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. SOLV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | SOLV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 53.50% | +13.90 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 18.70% | -10.00 | SOLV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 7.3x | +10.30 | SOLV | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | -0.07% | +5.36 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | 26.20% | -9.90 | SOLV | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 18.70% | -0.40 | SOLV | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 0.90% | +15.80 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 2.25 | +8.49 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 6/9 | +3.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.8 | 43.4 | +16.40 | GMED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.06 | +0.01 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 8.5x | +8.90 | SOLV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $14.22B | -$3.09B | SOLV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | SOLV REV | GMED GROSS % | SOLV GROSS % | GMED FCF | SOLV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $8.32B | 67.4% | 53.5% | $588.8M | -$10.0M |
| FY 2024 | $2.52B | $8.25B | 58.9% | 55.6% | $405.2M | $805.0M |
| FY 2023 | $1.57B | $8.20B | — | — | $172.9M | $1.55B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
SOLV // BETA 1.06